CAR-T Followed by Bispecific Antibodies

Summary

The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).

Timeline

Start

2021-11-05

Primary completion

2027-12-31

Completion

2028-12-31

Drugs

Indications